Skip to main content
Anna Chalmers
( out of 78 reviews )

Anna Chalmers, MD

Languages spoken: English

Clinical Locations

Primary Location

Sugar House Health Center

1280 E. Stringham Avenue
Salt Lake City , UT 84106

Anna Chalmers, M.D. is an Associate Professor in the Division of Oncology and an investigator at the Huntsman Cancer Institute. Dr. Chalmers is a specialist in adult medical oncology, with a focus in sarcoma. She joined the faculty in 2016 and sees patients at the Huntsman Cancer Institute in Salt Lake City and Sugarhouse.

Dr. Chalmers received her bachelor’s degree from Dartmouth College and her medical degree from Drexel University College of Medicine. She completed her residency in Internal Medicine and fellowship in Hematology and Medical Oncology at Rush University Medical Center in Chicago.

Dr. Chalmers is actively involved in research. She is committed to utilizing clinical studies to benefit her patients at the Huntsman Cancer Institute. She is a member of several international organizations, including the Connective Tissue Oncology Society and the American Society of Clinical Oncology.

Dr. Chalmers is a native of Newport Beach, California. She enjoys hiking, sailing, and skiing with her children and husband, who is an orthopedic surgeon at the University of Utah.

Specialties

Board Certification

American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine
American Board of Internal Medicine (Sub: Medical Oncology)

Patient Rating

4.9 /5
( out of 78 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

The scale on which responses are measured is 1 to 5 with 5 being the best score.

Patient Comments

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

HUNTSMAN CANCER CENTER

Dr Chalmers did everything to make me informed and at ease

HUNTSMAN CANCER CENTER

She explained things very well and listened to my concerns.

HUNTSMAN CANCER CENTER

extremely thorough, very caring

HUNTSMAN CANCER CENTER

Dr. Chanders is an Angel. Thanks for your help!

SUGAR HOUSE HEALTH CENTER

Dr. Chalmers gave me her collegues' recommendations as well as her own. Based on that I will undergo a regimen of radiation treatments at Logan Cancer Center starting [DATE REMOVED] to be followed by chemo therapy.

HUNTSMAN CANCER CENTER

She is absolutely amazing in her care and making sure you understand and like you are family

HUNTSMAN CANCER CENTER

Dr Chalmers is always caring and compassionate. She listens and understands my concerns.

HUNTSMAN CANCER CENTER

Very capable and a good listener

HUNTSMAN CANCER CENTER

She is interested in me and has a very pleasant happy way about her that makes being there a good experience.

Anna Chalmers, M.D. is an Associate Professor in the Division of Oncology and an investigator at the Huntsman Cancer Institute. Dr. Chalmers is a specialist in adult medical oncology, with a focus in sarcoma. She joined the faculty in 2016 and sees patients at the Huntsman Cancer Institute in Salt Lake City and Sugarhouse.

Dr. Chalmers received her bachelor’s degree from Dartmouth College and her medical degree from Drexel University College of Medicine. She completed her residency in Internal Medicine and fellowship in Hematology and Medical Oncology at Rush University Medical Center in Chicago.

Dr. Chalmers is actively involved in research. She is committed to utilizing clinical studies to benefit her patients at the Huntsman Cancer Institute. She is a member of several international organizations, including the Connective Tissue Oncology Society and the American Society of Clinical Oncology.

Dr. Chalmers is a native of Newport Beach, California. She enjoys hiking, sailing, and skiing with her children and husband, who is an orthopedic surgeon at the University of Utah.

Board Certification and Academic Information

Academic Departments Internal Medicine -Associate Professor (Clinical)
Academic Divisions Oncology
Board Certification
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine
American Board of Internal Medicine (Sub: Medical Oncology)

Education history

Undergraduate Dartmouth College B.A.
Professional Medical Medicine - Drexel University College of Medicine M.D.
Residency Internal Medicine - Rush University Medical Center Resident
Fellowship Hematology and Medical Oncology - Rush University Medical Center Fellow

Selected Publications

Journal Article

  1. Kerrigan K, Patel SB, Haaland B, Ose D, Weinberg Chalmers A, Haydell T, Meropol NJ, Akerley (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. JCO oncology practice, 16(4), e313-e323.
  2. Puri S, Malani R, Chalmers A, Kerrigan K, Patel SB, Monynahan K, Cannon L, Blouw B, Akerley (2023). Keeping a track on leptomeningeal disease in non-small cell lung cancer: A single-institution experience with CNSide(TM). Neuro-oncology advances, 6(1), vdad150.
  3. Chalmers AW, Patel S, Boucher K, Cannon L, Esplin M, Luckart J, Graves N, Van Duren T, Akerley (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Targeted oncology, 14(4), 417-421.
  4. Chalmers A, Cannon L, Akerley (2019). Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. The oncologist, 24(7), 963-972.

Editorial

  1. Chalmers AW, Patel SB, Akerley (2018). Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?. Journal of thoracic disease, 10(3), 1198-1200.

Letter

  1. Chalmers A, Akerley (2017). Retrospective, Multi-Institutional Analysis of Sequential Treatment of Brain Metastases in Treatment-Naïve, Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer Should Not Define the Standard of Practice. Journal of clinical oncology, 35(20), 2340.

Abstract

  1. Sandra P D'Angelo1 , Dejka M Araujo2 , Albiruni RA Razak3 , Andrew JS Furness4 , Brian AVan Tine5 , Mihaela Druta6 , Melissa A Burgess7 , Fiona Thistlethwaite8 , Anna W Chalmers9 , John B Haanen10 , Jonathan Noujaim11 , Richard F Riedel12 , David A Liebner13 , Neeta Somaiah2 , Warren A Chow14 , Rashmi Chugh15 , Lara E Davis16 , Ana Sebio17 , Mark Agulnik18 , Edouard Forcade19 , Michael J Wagner20 , Stephan A Grupp21 , Scott M Schuetze22 , Michael Carlton23 , Beth Ireland23 , Erin Van Winkle24 , Michael J Nathenson24 , Dennis Williams24 , Elliot Norry24 , John W Glod (2025). INTEGRATED EFFICACY AND SAFETY ANALYSIS OF LETETRESGENE AUTOLEUCEL, A T-CELL RECEPTOR T-CELL THERAPY, ACROSS CLINICAL TRIALS OF PATIENTS WITH SYNOVIAL SARCOMA AND MYXOID/ROUND CELL LIPOSARCOMA.
  2. Chia Jie Tan1, Connor Willis1, Timothy Bell2, Brad Tumminello2*, ShengfanZhou2, Dipam Doshi2, Carl Asche1, Joe Biskuspiak1, Diana Brixner1, Anna Chalmers3, David Stenehje DEVELOPMENT OF AN ALGORITHM TO IDENTIFY PATIENTS (PT) WITH DESMOID TUMORS (DT) IN A UNITED STATES (US) CLAIMS DATASET.